Overall, our data demonstrate that LDFI may represent a novel leptin receptor antagonist able to reduce breast cancer progression both in vitro and in vivo, suggesting its potential use in the treatment of breast cancer, especially in obese women. Here, LEPR is linked to breast carcinoma.